BioSpace News Archive

Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced the publication of two additional major clinical studies relating to its lead product, IsoPSA, for prostate cancer.

Bio-Rad Laboratories, Inc. today announced that the company’s management will participate in a Fireside Chat event during the Credit Suisse 31st Annual Healthcare Conference on Tuesday, November 8, 2022, at 11:00 AM (PST).

Abiomed (Nasdaq: ABMD) announces that Impella RP Flex with SmartAssist has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), the FDA’s highest level of approval, as safe and effective to treat acute right heart failure for up to 14 days.

Ainos, Inc. today announced that it is pursuing out-licensing opportunities for five new drug candidates for its low-dose oral interferon-alpha (“IFNα”) formulation, VELDONA®.

Hoth Therapeutics today announced positive data for BioLexa, its investigational therapeutic in a Phase 1b clinical trial in adult patients with mild-to-moderate atopic dermatitis.

Biocartis Group NV announces the publication of nine performance study abstracts of its fully automated molecular diagnostics Idylla™ platform1 and assays2 at the annual meeting of the ‘Association for Molecular Pathology’, a leading molecular diagnostics conference, taking place between 1-5 November in Phoenix, Arizona.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Cloutier Consulting, a Texas based public relations specialty agency, to provide media relations and related services for the Company.

The global population health management market size is estimated to surpass around USD 184.51 billion by 2030 from USD 41.25 billion in 2022, growing at a CAGR of 20.5%.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced that it will present new data from LIVMARLI® (maralixibat) oral solution studies, including two late-breaker presentations, at The Liver Meeting® of the American Association for the Study of Liver Diseases taking place November 4-7, 2022 in Washington, D.C.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its third quarter 2022 financial results on Monday, November 7, 2022 at 4:30 p.m. ET.